Diligence memo · auto-generated · as of July 2, 2026

Mevion Medical Systems, Inc.

Mevion Medical Systems, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Mevion Medical Systems, Inc. operates in Biotechnology, based in LITTLETON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Mevion Medical Systems, Inc. has raised $95M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $59M on 2015-07-24.

Most recent recorded round closed around 2015-07-24.

Valuation (modeled)modeled

Provath models Mevion Medical Systems, Inc. at approximately $2.4B (range $182M–$6.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.06× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era. Within the normal band (106% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 26 months.

Last raise 10.9 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 2.4× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 90% of Biotechnology peers (4293 compared).

Modeled value ranks above 95% of those peers.

Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc..

Peoplefiled

16 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.